Nurix Therapeutics 

Quarterly Financials

Values in thousands 2025-08-31 2025-05-31 2025-02-28 2024-11-30
Revenue
$7,894
$44,056
$18,453
$13,284
Gross Profit
2,894
44,056
18,453
13,284
EBITDA
-81,421
-37,607
-58,736
-60,354
EBIT
-86,421
-42,704
-62,864
-64,657
Net Income
-86,421
-43,464
-56,351
-58,549
Net Change In Cash
7,894
44,056
18,453
13,284
Free Cash Flow
-60,096
-65,836
-64,572
-50,856
Cash
78,438
84,260
75,916
109,997
Basic Shares
84,159
83,882
83,560
78,410

Annual Financials

Values in thousands 2024-11-30 2023-11-30 2022-11-30 2021-11-30
Revenue
$54,549
$76,987
$38,627
$29,750
Gross Profit
38,121
63,333
38,627
29,750
EBITDA
-196,599
-141,409
-173,059
-111,804
EBIT
-213,027
-155,063
-183,867
-117,886
Net Income
-193,569
-143,948
-166,045
-117,194
Net Change In Cash
54,549
76,987
38,627
29,750
Cost of Revenue
-15,417
-38,734
Free Cash Flow
-181,857
-89,766
-172,051
-90,026
Cash
109,997
54,627
64,474
80,506
Basic Shares
67,120
54,337
48,607
42,895

Earnings Calls

Quarter EPS
2025-11-30
$0
2025-08-31
-$1.03
2025-05-31
-$0.52
2025-02-28
-$0.67